Reuters • 2 days ago
Leaders of the global pharmaceutical industry, blasted by incoming U.S. President Donald Trump for "getting away with murder" on drug prices, are putting a brave face on the challenges in their biggest market.
Reuters • 2 days ago
PARIS/DAVOS, Switzerland (Reuters) - For the last year, Sanofi's chief executive has made clear his quest for deals to help revive the fortunes of France's biggest drugmaker. Olivier Brandicourt's failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors. In an interview at the World Economic Forum in the Swiss resort of Davos this week Brandicourt defended his track record, citing an unwillingness to overpay for pricey assets and a paucity of good opportunities.
The Wall Street Journal • 2 days ago
The maker of an EpiPen rival said its emergency allergy treatment would return to the market on Feb. 14, adding more competition to the market for the costly products.
The Wall Street Journal • 3 days ago
Irish drugmaker Mallinckrodt and a U.S. subsidiary will pay $100 million and agree to other conditions to settle government antitrust allegations they unlawfully prevented competition for Acthar, a drug ...
Zacks • 3 days ago
Sanofi (SNY) announced that the European Commission has granted marketing authorization to its once-daily injection, Suliqua a combination of diabetes drugs Lantus and lixisenatide for the treatment of diabetes.
Reuters • 3 days ago
Two decades after they were spurred into action to tackle AIDS in Africa, global drugmakers said on Wednesday they would invest an initial $50 million over three years to fight cancer and other non-communicable diseases in poor countries. Twenty-two companies, including Pfizer, Merck , Novartis, Roche, Sanofi and GlaxoSmithKline, will contribute funds and expertise to the project, which is backed by the World Bank. The so-called Access Accelerated initiative was announced at the World Economic Forum in Davos and aims to improve both treatment and prevention.
Financial Times • 4 days ago
More than 20 of the world's leading drug companies have pledged to work together to treat cancer and other non-communicable diseases in poor and developing countries. Cancer and non-transmitted diseases ...
Forbes • 5 days ago
Trump hasn’t yet entered the Oval Office, but he’s already showing an uncanny knack for creating quick stock dips with just a sentence or two.
SAN.PA : Summary for SANOFI - Yahoo Finance
Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||75.20 - 76.43|
|52 Week Range||62.50 - 79.07|
|PE Ratio (TTM)||23.20|
|Earnings Date||Feb 8, 2017|
|Dividend & Yield||3.35 (4.12%)|
|1y Target Est||86.71|